Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PROK Stock Forecast 2026-2027
$1.55
Current Price
$468.19M
Market Cap
Buy 4
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to PROK Price Targets
+674.2%
To High Target of $12.00
+271.0%
To Median Target of $5.75
-35.5%
To Low Target of $1.00
PROK Price Momentum
-15.8%
1 Week Change
-7.2%
1 Month Change
-54.0%
1 Year Change
-30.8%
Year-to-Date Change
-68.7%
From 52W High of $4.95
+1.3%
From 52W Low of $1.53
📊 TOP ANALYST CALLS
Did PROK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ProKidney is one of their latest high-conviction picks.
Latest PROK Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PROK has a bullish consensus with a median price target of $5.75 (ranging from $1.00 to $12.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.55, the median forecast implies a 271.0% upside. This outlook is supported by 4 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 674.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PROK Analyst Ratings
4
Buy
2
Hold
1
Sell
PROK Price Target Range
Low
$1.00
Average
$5.75
High
$12.00
Current: $1.55
Latest PROK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PROK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 18, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $12.00 |
| Dec 16, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jul 15, 2025 | UBS | Buy | Maintains | $N/A | |
| Jul 14, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Jul 9, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Jun 30, 2025 | B of A Securities | Underperform | Downgrade | $N/A | |
| Sep 30, 2024 | JP Morgan | Neutral | Initiates | $N/A | |
| Sep 10, 2024 | Guggenheim | Buy | Initiates | $N/A | |
| Sep 4, 2024 | B of A Securities | Neutral | Maintains | $N/A | |
| Jun 10, 2024 | Jefferies | Buy | Maintains | $N/A | |
| May 29, 2024 | B of A Securities | Neutral | Maintains | $N/A | |
| Mar 7, 2024 | Morgan Stanley | Judah Frommer | Equal-Weight | Assumes | $3.00 |
| Jan 2, 2024 | B of A Securities | Neutral | Downgrade | $N/A | |
| Jul 25, 2023 | BTIG | Buy | Initiates | $N/A | |
| Dec 21, 2022 | Jefferies | Buy | Initiates | $N/A | |
| Nov 10, 2022 | Morgan Stanley | Equal-Weight | Initiates | $N/A | |
| Oct 18, 2022 | UBS | Buy | Initiates | $N/A | |
| Oct 14, 2022 | Citigroup | Buy | Initiates | $N/A | |
| Sep 2, 2022 | Evercore ISI Group | Outperform | Initiates | $N/A |
ProKidney Corp (PROK) Competitors
The following stocks are similar to ProKidney based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProKidney Corp (PROK) Financial Data
ProKidney Corp has a market capitalization of $468.19M with a P/E ratio of -3.0x. The company generates $889,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -1.7% quarter-over-quarter, while maintaining an operating margin of -19,881.9% and return on equity of -49.4%.
Valuation Metrics
Market Cap
$468.19M
Enterprise Value
$1.40B
P/E Ratio
-3.0x
PEG Ratio
-0.4x
Price/Sales
547.0x
Growth & Margins
Revenue Growth (YoY)
-1.7%
Gross Margin
N/A
Operating Margin
-19,881.9%
Net Margin
0.0%
EPS Growth
-1.7%
Financial Health
Cash/Price Ratio
+70.7%
Current Ratio
9.1x
Debt/Equity
1.4x
ROE
-49.4%
ROA
-30.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ProKidney Corp (PROK) Business Model
About ProKidney Corp
What They Do
Develops cell therapies for chronic kidney disease.
Business Model
ProKidney Corp operates within the biopharmaceutical industry, focusing on regenerative medicine to treat chronic kidney disease (CKD). The company generates revenue by developing and commercializing its innovative therapies, particularly through its flagship REACT program, which aims to repair kidney tissues using autologous cell therapy. Clinical trials and partnerships with healthcare institutions enhance its market position and potential profitability.
Additional Information
CKD is a significant global health issue, and ProKidney's solutions could reduce reliance on costly dialysis and transplants. The company is positioned to impact the biotechnology sector positively by improving patient outcomes and lowering healthcare costs, thereby addressing the growing demand for effective chronic disease management.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
231
CEO
Dr. Bruce Culleton M.D.
Country
United States
IPO Year
2022
Website
prokidney.comProKidney Corp (PROK) Latest News & Analysis
Latest News
Quick Summary
Kenneth Locke has been appointed Chief Technical Officer at ProKidney, leveraging 25 years of experience in CMC and Supply Chain to advance the commercialization of rilparencel.
Why It Matters
Kenneth Locke's appointment as CTO enhances ProKidney's leadership, crucial for advancing rilparencel's commercialization, potentially boosting investor confidence and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProKidney Corp. (Nasdaq: PROK) reported its Q1 2026 financial results and business highlights, focusing on its late-stage cell therapy for chronic kidney disease.
Why It Matters
ProKidney's Q1 financial results and business updates signal its progress in the cell therapy market for chronic kidney disease, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProKidney Corp. (PROK) reported a quarterly loss of $0.14 per share, slightly worse than the expected loss of $0.13, and compared to a loss of $0.13 per share in the previous year.
Why It Matters
ProKidney's larger-than-expected quarterly loss signals financial struggles, potentially impacting investor confidence and stock performance. Negative earnings could lead to a reassessment of growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Negative
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
3 months ago
Quick Summary
ProKidney Corp. (Nasdaq: PROK) appointed Greg Madison as Chief Commercial Officer, advancing its focus on chronic kidney disease (CKD) therapies.
Why It Matters
The appointment of Greg Madison as CCO may signal strategic growth and commercialization efforts for ProKidney, potentially impacting stock performance and investor confidence in the company's future.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PROK's key asset, Rilparencel, is in the PROACT 1 pivotal trial. The FDA accepted eGFR slope analysis for potential accelerated approval, with topline results expected by Q2 2027.
Why It Matters
PROK's pivotal trial and FDA acceptance of eGFR slope analysis signal potential accelerated approval, enhancing its valuation and future growth prospects.
Source: Seeking Alpha
Market Sentiment:
Positive
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
6 months ago
Quick Summary
ProKidney Corp. (PROK) presented at the 44th Annual J.P. Morgan Healthcare Conference, indicating potential insights into its business and outlook.
Why It Matters
ProKidney's presentation at a major healthcare conference can signal potential growth opportunities, partnerships, or innovations, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PROK Stock
What is ProKidney Corp's (PROK) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, ProKidney Corp (PROK) has a median price target of $5.75. The highest price target is $12.00 and the lowest is $1.00.
Is PROK stock a good investment in 2027?
According to current analyst ratings, PROK has 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PROK stock?
Wall Street analysts predict PROK stock could reach $5.75 in the next 12 months. This represents a 271.0% increase from the current price of $1.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProKidney Corp's business model?
ProKidney Corp operates within the biopharmaceutical industry, focusing on regenerative medicine to treat chronic kidney disease (CKD). The company generates revenue by developing and commercializing its innovative therapies, particularly through its flagship REACT program, which aims to repair kidney tissues using autologous cell therapy. Clinical trials and partnerships with healthcare institutions enhance its market position and potential profitability.
What is the highest forecasted price for PROK ProKidney Corp?
The highest price target for PROK is $12.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 674.2% increase from the current price of $1.55.
What is the lowest forecasted price for PROK ProKidney Corp?
The lowest price target for PROK is $1.00 from at , which represents a -35.5% decrease from the current price of $1.55.
What is the overall PROK consensus from analysts for ProKidney Corp?
The overall analyst consensus for PROK is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $5.75.
How accurate are PROK stock price projections?
Stock price projections, including those for ProKidney Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 12:06 PM UTC